Evidence map›Paper›PMID 38688637›Full record

ArticleIn vivo (Athens, Greece)

Pure Red Cell Aplasia and Chromosomal Abnormality in a Patient With Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors: A Case Report.

Takahiro Hirai, Minehiko Inomata, Shuhei Minatoyama, Moe Hashizume, Naoki Takata, Kana Hayashi, Zenta Seto, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa and 7 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Takahiro HiraiFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Minehiko InomataFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan; 9446-tym@umin.org.
Shuhei MinatoyamaFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Moe HashizumeFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Naoki TakataFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Kana HayashiFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Zenta SetoFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Kotaro TokuiFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Chihiro TakaFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Seisuke OkazawaFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Kenta KambaraFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Shingo ImanishiFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Toshiro MiwaFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Ryuji HayashiDepartment of Medical Oncology, Toyama University Hospital, Toyama, Japan.
Shinichi TanakaDepartment of Diagnostic Pathology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Akira NoguchiDepartment of Diagnostic Pathology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Tsutomu SatoDepartment of Hematology, Toyama University Hospital, Toyama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimImmune checkpoint inhibitors can induce immune-related adverse events in various organs, thus careful observation is required. CASE REPORT: A 69-year-old man was diagnosed with advanced lung adenocarcinoma and treated with combined therapy of carboplatin plus pemetrexed plus pembrolizumab. After two cycles of treatment, anemia was noted. Myelosuppression due to cytotoxic anticancer agents was suspected and the cytotoxic agents were discontinued, followed by three courses of pembrolizumab monotherapy. However, the anemia persisted, requiring red blood cell transfusions. A bone marrow biopsy revealed erythroblast hypoplasia and chromosomal abnormalities, resulting in a diagnosis of pure red cell aplasia. These adverse events were considered immune-related because of the treatment history with an immune checkpoint inhibitor, and 60 mg/day (1 mg/kg/day) of prednisolone was initiated. Anemia improved, and it did not recur during the tapering of prednisolone.

conclusionImmune-related pure red cell aplasia should be considered for patients presenting anemia during treatment with immune checkpoint inhibitors.

Indexed as

Adenocarcinoma of LungAntibodies, Monoclonal, HumanizedChromosome AberrationsImmune Checkpoint InhibitorsLung NeoplasmsRed-Cell Aplasia, PureAgedAntineoplastic Combined Chemotherapy ProtocolsHumansMaleAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorspembrolizumabAnemialung cancermyelodysplasia syndromepembrolizumab

Identifiers

PMID38688637
PMCPMC11059905

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.